Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 12/2016

01-12-2016 | Original Article

The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF

Authors: L. Kotanidis, K. Nikolettos, S. Petousis, B. Asimakopoulos, E. Chatzimitrou, G. Kolios, N. Nikolettos

Published in: Journal of Endocrinological Investigation | Issue 12/2016

Login to get access

Abstract

Aim

To investigate the predictive value of anti-Mullerian hormone (AMH) and antral follicle count (AFC) on the final number of oocytes retrieved and the availability of embryos for cryopreservation in in vitro fertilization (IVF) cycles.

Patients and methods

In this prospective study, one hundred and twenty women in their first IVF treatment were enrolled. The short stimulation agonist protocol was used for controlled ovarian hyperstimulation in all cases. Serum AMH levels were measured during the menstrual cycle preceding treatment. AFC was measured in cycle day 2, just before starting ovarian stimulation.

Results

A strong, positive correlation between AMH, AFC and the number of collected oocytes was found. The patients with available and suitable supplementary embryos for cryopreservation had higher levels of AMH and larger numbers of AFC.

Conclusion

AMH and AFC appear to be valuable markers mainly for ovarian reserve and response to IVF treatment. Serum AMH levels and AFC are significantly associated with the number of retrieved oocytes. Also, a positive correlation with the availability of supernumerary embryos suitable for cryopreservation was observed.
Literature
1.
Te Velde ER, Scheffer GJ, Dorland M, Broekmans FJ, Fauser BC (1998) Developmental and endocrine aspects of normal ovarian aging. Mol Cell Endocrinol 145:67–73CrossRef
2.
La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A (2007) Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 22(3):766–771CrossRefPubMed
3.
Chang MY, Chiang CH, Hsieh TT, Soong YK, Hsu KH (1998) Use of the antral follicle count to predict the outcome of assisted reproductive technologies. Fertil Steril 69:505–510CrossRefPubMed
4.
5.
Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW, te Velde ER (1999) Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility. Fertil Steril 72:845–851CrossRefPubMed
6.
Kline J, Kinney A, Kelly A, Reuss ML, Levin B (2005) Predictors of antral follicle count during the reproductive years. Hum Reprod 20:2179–2189CrossRefPubMed
7.
Pavone ME, Innes J, Hirshfeld-Cytron J, Kazer R, Zhang J (2011) Comparing thaw survival, implantation and live birth rates from cryopreserved zygotes, embryos and blastocysts. J Hum Reprod Sci 4(1):23–28CrossRefPubMedPubMedCentral
8.
Gougeon A: Ovarian follicular growth in humans (1998) ovarian ageing and population of growing follicles. Maturitas 30(2):137–142CrossRef
9.
Scheffer GJ, Broekmans FJM, Looman CWN, Blankenstein M, Fauser BCJM, de Jong FH, te Velde ER (2003) The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 18:700–706CrossRefPubMed
10.
Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER (2004) Impact of repeated antral follicle counts on the prediction of poor ovarian response in women undergoing in vitro fertilization. Fertil Steril 81:35–41CrossRefPubMed
11.
Bancsi LFJMM, Broekmans FJM, Eijkemans MJC, de Jong FH, Habbema JD, te Velde ER (2002) Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 77:328–336CrossRefPubMed
12.
Van Rooij IA, Tonkelaar I, Broekmans FJ, Looman CW, Scheffer GJ, de Jong FH, Themmen AP, te Velde ER (2004) Anti-mullerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11:601–606CrossRefPubMed
13.
Tsakos E, Tolikas A, Daniilidis A, Asimakopoulos B (2014) Predictive value of anti-Müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET. Arch Gynecol Obstet 290(6):1249–1253. doi:10.​1007/​s00404-014-3332-3 CrossRefPubMed
14.
He Y, Xia R, Chen X, Ye D, Tang Y, Li P, Niu J, Chen S (2013) Estimation of ovarian response using multiple predictors of ovarian reserve in women undergoing in vitro fertilization-embryo transfer. Nan Fang Yi Ke Da Xue Xue Bao 33(2):216–220PubMed
15.
Mutlu MF, Erdem M, Erdem A, Yildiz S, Mutlu I, Arisoy O, Oktem M (2013) Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles. J Assist Reprod Genet 30(5):657–665. doi:10.​1007/​s10815-013-9975-3 CrossRefPubMedPubMedCentral
16.
Tolikas A, Tsakos E, Gerou S, Prapas Y, Loufopoulos A (2011) Anti-Mullerian hormone (AMH) levels in serum and follicular fluid as predictors of ovarian response in stimulated (IVF and ICSI) cycles. Hum Fertil (Camb) 14(4):246–253. doi:10.​3109/​14647273.​2011.​608464 CrossRef
17.
18.
Kotanidis L, Asimakopoulos B, Nikolettos N (2013) Association between AMH, oocyte number and availability of embryos for cryopreservation in IVF. In Vivo 27(6):877–880PubMed
19.
Veek LL et al (1992) Oocyte quality and assisted conception. Acta Eur Fertil 23(6):275–288
20.
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P (2004) Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82(5):1323–1329CrossRefPubMed
21.
Sönmezer M, Özmen B, Atabekoglu CS, Papuccu EG, Ozkavukcu S, Berker B, Pabuccu R (2012) Serum anti-Mullerian hormone levels correlate with ovarian response in idiopathic hypogonadotropic hypogonadism. J Assist Reprod Genet 29(7):597–602CrossRefPubMedPubMedCentral
22.
Smeenk JM, Sweep FC, Zielhuis GA, Kremer JA, Thomas CM, Braat DD (2007) Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracytoplasmic sperm injection. Fertil Steril 87(1):223–226CrossRefPubMed
23.
Patrelli TS, Gizzo S, Sianesi N, Levati L, Pezzuto A, Ferrari B, Modena AB (2012) Anti-mullerian hormone serum values and ovarian reserve: can it predict a decrease in fertility after ovarian stimulation by assisted reproduction technique (ART) cycles? PLoS One 7(9):e44571CrossRefPubMedPubMedCentral
24.
Sriharibabu M, Himabindu Y, Gopinathan KK, Pandey AK, Fessy Louis T, Gopinath P (2012) Association of day 3 antimullerian hormone (AMH) with oocyte quality, fertilization rates and grade 1 embryos. Biomed 36:61–66
25.
Sills ES, Collins GS, Brady AC, Walsh DJ, Marron KD, Peck AC, Walsh AP, Salem RD (2011) Bivariate analysis of basal serum anti-Müllerian hormone measurements and human blastocyst development after IVF. Reprod Biol Endocrinol 9:153CrossRefPubMedPubMedCentral
26.
Negm SMM, Kamel RA, Magdi AM, Abuhamila FA, Al-Mohamady M (2012) Serum anti-Mullerian hormone and basal serum FSH as predictors of poor ovarian response in assisted conception cycles. Middle East Fertil Soc J 17(4):283–289CrossRef
27.
Fridén B, Sjöblom P, Menezes J (2011) Using anti-Mullerian hormone to identify a good prognosis group in women of advanced reproductive age. Aust N Z J Obstet Gynaecol 51(5):411–415CrossRefPubMed
28.
Arabzadeh S, Hossein G, Rashidi BH, Hosseini MA, Zeraati H (2010) Comparing serum basal and follicular fluid levels of anti-Müllerian hormone as a predictor of invitro fertilization outcomes in patients with and without polycystic ovary syndrome. Ann Saudi Med 30(6):442–447PubMedPubMedCentral
29.
Wunder DM, Guibourdenche J, Birkhäuser MH, Bersinger NA (2008) Anti-Mullerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 90(6):2203–2210CrossRefPubMed
30.
Andersen AN, Witjes H, Gordon K, Mannaerts B (2011) Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 26(12):3413–3423CrossRefPubMed
31.
Anckaert E, Smitz J, Schiettecatte J, Klein BM, Arce JC (2012) The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments. Hum Reprod 27(6):1829–1839CrossRefPubMedPubMedCentral
32.
Lie Fong S, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, de Jong FH, Fauser BJ, Laven JS (2008) Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reprod Biomed Online 16(5):664–670CrossRefPubMed
33.
Heidar Z, Bakhtiyari M, Mirzamoradi M, Zadehmodarres S, Sarfjoo FS, Mansournia MA (2015) Prediction of different ovarian responses using anti-Müllerian hormone following a long agonist treatment protocol for IVF. J Endocrinol Invest 38:1007–1015CrossRefPubMed
34.
Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Isaka K (2008) Anti-Mullerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril 89(3):586–591CrossRefPubMed
35.
Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S (2011) Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol 284(5):1295–1301CrossRef
Metadata
Title
The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF
Authors
L. Kotanidis
K. Nikolettos
S. Petousis
B. Asimakopoulos
E. Chatzimitrou
G. Kolios
N. Nikolettos
Publication date
01-12-2016
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 12/2016
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0521-x

Other articles of this Issue 12/2016

Journal of Endocrinological Investigation 12/2016 Go to the issue

Original Article

Does vitamin D have any role in the improvement of diabetic peripheral neuropathy in type 1 diabetic patients?

Consensus Statement

Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association

Review

Insulin, insulin receptors, and cancer

Original Article

Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing’s disease harbouring microadenomas or macroadenomas

Original Article

Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes

Original Article

Relationship of galectin-3 with obesity, IL-6, and CRP in women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits